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Abstract
 
Activation-induced cell death (AICD) is a mechanism of peripheral T cell tolerance that de-
pends upon an interaction between Fas and Fas ligand (FasL). Although c-Jun NH
 
2
 
-terminal
kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) may be involved in apoptosis
in various cell types, the mode of regulation of FasL expression during AICD in T cells by
these two MAPKs is incompletely understood. To investigate the regulatory roles of these two
MAPKs, we analyzed the kinetics of TCR-induced p38 MAPK and JNK activity and their
regulation of FasL expression and AICD. We report that both JNK and p38 MAPK regulate
AICD in T cells. Our data suggest a novel model of T cell AICD in which p38 MAPK acts
early to initiate FasL expression and the Fas-mediated activation of caspases. Subsequently,
caspases stimulate JNK to further upregulate FasL expression. Thus, p38 MAPK and down-
stream JNK converge to regulate FasL expression at different times after T cell receptor stimu-
lation to elicit maximum AICD.
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Introduction
 
Lymphocyte development is regulated not only by prolifer-
ation and differentiation but also by cell death or apoptosis
(1). Lymphocyte apoptosis is believed to maintain homeo-
stasis and self-tolerance in the immune system. For exam-
ple, thymocytes that fail to rearrange their TCR gene will
die by neglect, and those that recognize self-antigens will
be eliminated by apoptosis, a process called negative selec-
tion. In peripheral T cells, a form of apoptosis induced by
repeated TCR stimulation, known as activation-induced
cell death (AICD),
 
1
 
 may be responsible for the peripheral
deletion of autoreactive T cells (2, 3). AICD results from
the interaction between Fas and Fas ligand (FasL), and acti-
vated T cells expressing both Fas and FasL are killed either
by themselves or by interacting with each other (4–6).
Thus, a defect in AICD of effector T cells may result in the
development of an autoimmune disease (7, 8). In support
of this notion, mutations in Fas or FasL result in a systemic
lupus–like autoimmune disease in mice (9) and humans
(10, 11), illustrating a critical role for AICD in the mainte-
nance of self-tolerance.
The signaling mechanisms of Fas-mediated cell death are
not fully understood, but caspases play a crucial role in apop-
totic processes (12–14). At least two distinct caspase activi-
ties are required for completion of the apoptotic pathway
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(15–21). One preferentially cleaves a YVAD tetrapeptide
substrate, whereas the other preferentially cleaves a DEVD
tetrapeptide substrate (22). In the simplest scheme, binding
of FasL to Fas induces trimerization of the Fas receptor, and
Fas-associated death domain (FADD) binds to the trimer-
ized Fas cytoplasmic region through the interaction of the
respective death domains. Procaspase-8 is then recruited to
FADD through binding of the death effector domains. This
is a death-inducing signaling complex in which the aggre-
gated procaspase-8 transactivates (23). The active caspase-8
then acts to cleave and activate the downstream caspases
that culminate in apoptosis (1, 24, 25). However, the
mechanism by which the apoptotic process is executed is
unclear.
Signal transduction by mitogen-activated protein kinases
(MAPKs) plays a key role in a variety of cellular responses,
including proliferation, differentiation, and cell death (26,
27). Recently, two subfamily members of the MAPK su-
perfamily, c-Jun NH
 
2
 
-terminal kinase (JNK) and p38
MAPK, have been implicated in several types of apoptosis
(28–33). The role of JNK in apoptosis has been debated for
several reasons (34–38). First, thymocytes from stress-acti-
vated protein kinase/extracellular signal–regulated kinase
(an upstream activator of JNK) deficient mice are more sus-
ceptible to anti-CD3–induced apoptosis (37). Second, JNK
and activator protein (AP)-1 do not mediate Fas-induced
apoptosis in human Jurkat T cells (34). Third, activation of
JNK by TNF occurs independent of TNF-induced apop-
tosis (38). Thus, the activation of JNK that ensues upon
anti-Fas stimulation may occur subsequent to the activation
of the caspase cascade, and a JNK cascade may be redun-
dant or arise secondary to cellular damage associated with
apoptosis (1, 35, 39–41).
Recent evidence indicates that JNK may commit T cells
to stress-induced apoptosis through FasL expression (42,
43). Most importantly, AICD in T cells is significantly im-
paired in JNK-1– and JNK-2–deficient mice (44, 45), sug-
gesting that JNK is actively involved in the regulation of
AICD in primary T cells. However, the mechanism by
which JNK regulates T cell AICD remains to be eluci-
dated. Studies using Jurkat T cells suggest that Fas-depen-
dent activation of p38 MAPK requires caspase-1–like fam-
ily members in Jurkat T cells (46) and that MAP kinase
kinase
 
 
 
(MKK)3 or MKK6b but not p38 MAPK is involved
in anti-Fas–induced apoptosis (46, 47). Note that because
Jurkat T cells constitutively express a high level of Fas, the
mechanism of cell death induced by anti-Fas stimulation of
these T cells may differ from that induced by FasL ligation.
Notwithstanding, we found in pilot studies that other T
cells that express low levels of Fas and FasL, including
DO11.10 T hybridoma cells and primary naive splenic T
cells, are relatively resistant to anti-Fas–induced T cell
death. Moreover, we also showed that Jurkat T cells and
primary T cells differ in their requirements for MAPK acti-
vation, and that p38 MAPK is a critical molecule involved
in T cell activation in primary T cells (27). Inasmuch as the
upregulation of FasL expression in primary T cells requires
activation signals through the TCR (48, 49), it is possible
 
that p38 MAPK plays an important role in the regulation of
FasL expression. Thus, the regulation of FasL expression
during AICD by p38 MAPK and JNK is not well under-
stood and merits further investigation.
In this study, we investigated the role of p38 MAPK
and JNK in the control of FasL expression during TCR-
induced AICD. We demonstrate that p38 MAPK plays a key
role in the initiation of FasL expression and the Fas-medi-
ated activation of caspases and JNK. Caspase inhibitors do
not block the activation of p38 MAPK during AICD, and
JNK activation requires caspase activity. Moreover, inhibi-
tion of p38 MAPK activity by SB203580 blocks the activa-
tion of caspases. Our observations suggest that (a) p38
MAPK is an upstream regulator of caspases and (b) JNK
functions downstream of the caspases. Interestingly, FasL
expression is downregulated by caspase inhibitors and a
dominant negative (DN) JNK. These data favor a model of
T cell AICD in which p38 MAPK and downstream JNK
converge to regulate FasL expression at different times after
TCR stimulation to elicit maximum T cell AICD.
 
Materials and Methods
 
Mice.
 
C57BL/6J (B6) mice were obtained from Taconic
Farms Inc., and B6Smn.C3H-FasL
 
gld
 
 (gld) mice were pur-
chased  from The Jackson Laboratory. The mice were bred in the
Animal Care Facility at the University of Western Ontario (Lon-
don, ON, Canada). All mice used in these experiments were 6–8
wk old.
 
Reagents and Cell Culture.
 
The following reagents were pur-
chased from Santa Cruz Biotechnology: rabbit polyclonal anti-
bodies against mouse extracellular signal–regulated kinase
(ERK)1, p38 MAPK, caspase-1 (M20), glutathione–agarose,
glutathione-
 
S
 
-transferase (GST)–c-Jun (1-79), and GST–ATF-2
(activating transcription factor 2; 1-505). YVAD–chloromethyl
ketone, DEVD–fluoromethyl ketone (FMK), and zVAD–FMK
were purchased from Cedarlane Labs. The 145-2C11 anti-CD3
and 37.51 anti-CD28 mAbs were purified by protein G affinity
chromatography (Santa Cruz Biotechnology) of the supernatants
of the B cell hybridomas supplied by Dr. J. Bluestone (Uni-
versity of Chicago, Chicago, IL) and Dr. J. Allison (Univer-
sity of California, Berkeley, CA), respectively. An anti-CPP32
(caspase-3) antiserum was a gift from Dr. R.-P. Sékaly (Univer-
sity of Montreal, Montreal, PQ, Canada). The p38 MAPK in-
hibitor 203580 and its inactive form, SKF106978, were provided
by Dr. P. Young (SmithKline Beecham Pharmaceuticals, King
of Prussia, PA). Recombinant human IL-2 (rIL-2) and myelin
basic protein (MBP) were purchased from Sigma Chemical
Co. Ac-YVAD–AMC (7-amino-4-methylcoumarin) and Ac-
DEVD–AFC (7-amino-4-trifluoromethylcoumarin) were purchased
from PharMingen. A Fas-Fc chimeric protein was obtained from
Dr. D. Green (La Jolla Institute for Allergy and Immunology,
San Diego, CA). The DO11.10 T cell hybridoma was obtained
from Dr. B. Singh (University of Western Ontario, London,
ON, Canada) and grown in RPMI 1640 medium supplemented
with 10% heat-inactivated FCS, 10 mM Hepes, 0.1 mg/ml
streptomycin, 100 U/ml penicillin, 0.05 mM 2-ME, and 2 mM
glutamine (all purchased from GIBCO BRL). rIL-2 was pur-
chased from Sigma Chemical Co.
 
Plasmids.
 
The DN p38 mutant (p38 [M], K
 
57
 
 to M) in
pcDNA3 was supplied by Dr. J. Han (Scripps Research Institute, 
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La Jolla, CA). The wild-type (WT) stress-activated protein ki-
nase (SAPK)
 
a
 
 and DN SAPK
 
a
 
 constructs were gifts from Dr. E.
Nishida (Kyoto University, Kyoto, Japan). The DN JNK
(SAPK
 
a
 
–VPF) was constructed by replacement of the phosphor-
ylation sites threonine and tyrosine with valine and phenylala-
nine, respectively. The WT or DN SAPK
 
a
 
 coding region was
inserted into the pSR
 
a
 
-HA1 vector as described (50). Hereafter,
we will refer to the WT SAPK
 
a
 
 or DN SAPK
 
a
 
 constructs as
WT–JNK-2 and DN–JNK-2, respectively. The human FasL
promoter construct, which contains 511 bp 5
 
9
 
 upstream of the
FasL gene cloned into the luciferase reporter construct pGL3,
was a gift from Dr. J. Ashwell (National Cancer Institute, Na-
tional Institutes of Health, Bethesda, MD). This 511-bp se-
quence contains the major regulatory element(s) for the FasL
gene (51).
 
T Cell Isolation and Activation.
 
Splenic T cells from naive B6
mice were isolated (purity 
 
$
 
98% as determined by FACS
 
®
 
 anal-
ysis of CD3
 
1
 
 cell surface expression) on T cell enrichment col-
umns (R & D Systems, Inc.). For in vitro activation, B6 T cells
(2 
 
3
 
 10
 
6
 
 per milliliter) were stimulated with plate-bound anti-
CD3 (10 
 
m
 
g/ml) and anti-CD28 (5 
 
m
 
g/ml) mAbs in 24-well
plates and then cultured for 48 h in complete RPMI 1640. Via-
ble cells were recovered for restimulation.
 
Induction and Analysis of AICD.
 
DO11.10 T hybridoma cells
(2 
 
3
 
 10
 
6
 
 per milliliter) were cultured in triplicate in 24-well
plates precoated with 10 
 
m
 
g/ml anti-CD3 for either 16 h or the
times indicated (see Figs. 1–5). Alternatively, in vitro–activated
B6 splenic T cells were either left unstimulated or were restimu-
lated with plate-bound anti-CD3 for 16 h in the presence of rIL-2
(20 U/ml). Viability was assessed by addition of 10 
 
m
 
g/ml pro-
pidium iodide (PI) and immediate analysis using a FACScan™
(Becton Dickinson). Apoptotic cells were identified as those cells
that stained positive for PI. Chromosomal DNA was isolated us-
ing a DNA purification kit (QIAGEN Inc.) according to the
manufacturer’s instructions, and T cell AICD was monitored by
DNA fragmentation visualized after analysis of the samples on a
2% agarose gel in Tris-borate–EDTA.
 
In Vitro Kinase Assay.
 
After stimulation, cells were lysed in
ice-cold lysis buffer containing 1% Triton X-100, 10 mM Tris,
pH 7.5, 150 mM NaCl, 2 mM EGTA, 50 mM 
 
b
 
-glycerophos-
phate, 2 mM Na
 
3
 
VO
 
4
 
, 10 mM NaF, 1 mM dithiothreitol
(DTT), 1 mM PMSF, 10 
 
m
 
g/ml leupeptin, and 10 
 
m
 
g/ml apro-
tinin. Lysates were clarified by centrifugation at 12,000 rpm for
10 min at 4
 
8
 
C, and their protein content was determined by the
Bradford assay using BSA as a standard. Kinase assays for ERK1
and p38 MAPK and solid-phase JNK assays were performed es-
sentially as described (27). Equal loading of precipitated proteins
was confirmed by probing the blots with specific antibodies, and
phosphorylation of the fusion protein or MBP bands was quanti-
tated using a Molecular Imager System and Molecular Analyst
imaging software (Bio-Rad Labs.).
 
Western Blotting.
 
Cell lysates were resolved on SDS-PAGE
and transferred to nitrocellulose membranes (Hy-bond C Super;
Amersham). Blots were blocked for 1 h at 23
 
8
 
C in PBS contain-
ing 2% BSA and 0.05% Tween-20. Membranes were incubated
overnight with rabbit antisera to human CPP32 (caspase-3),
caspase-1, or other rabbit-specific antibodies and were then
washed three times in PBS containing 0.05% Tween-20.
Caspase-1 and caspase-3 were detected using horseradish peroxi-
dase–conjugated goat anti–rabbit IgG (Santa Cruz Biotechnol-
ogy). After three washes in PBS containing 0.05% Tween-20,
signals were revealed by ECL Western blotting (Amersham) and
visualized by autoradiography.
 
Cell Transfection.
 
DO11.10 T cells (5 
 
3
 
 10
 
5
 
 per milliliter)
were transfected with LipofectAMINE PLUS (GIBCO BRL) as
recommended by the manufacturer. Exponentially growing cells
were washed twice with PBS and resuspended in Opti-MEM
(GIBCO BRL). The plasmids (5 
 
m
 
g/ml) were preincubated with
PLUS reagent for 15 min at 23
 
8
 
C, and the precomplexed plas-
mids were then incubated for 5 h at 37
 
8
 
C with a mixture of 1
 
m
 
g/ml pCMV vector expressing green fluorescence protein
(GFP) and 6 
 
m
 
l of LipofectAMINE in 1.5 ml of Opti-MEM.
Cells were washed twice with complete RPMI 1640, incubated
for 36 h, and then selected in 600 
 
m
 
g/ml G418 for 3 wk. Trans-
fection efficiencies were assessed by FACScan™ analyses of GFP
expression and in vitro kinase assays of enzyme activity.
 
Luciferase Assay.
 
p38 (M) or pcDNA3 DO11.10 stable trans-
fectants (5 
 
3
 
 10
 
5
 
 cells per milliliter) were transfected with 1 
 
m
 
g of
a FasL promoter–reporter construct. Cells were grown in com-
plete RPMI 1640 medium for 48 h at 37
 
8
 
C. The cells were either
left unstimulated or were stimulated with plate-bound anti-CD3
for 16 h, washed, and then lysed in luciferase buffer. Luciferase
activity was monitored using a luciferase reporter gene assay kit
(Roche Labs.), and luminescence was detected in a scintillation
counter (Beckman Instruments). Transfection efficiency was
monitored by cotransfection of a 
 
b
 
-galactosidase–encoding plas-
mid (pUC19) and measurement of the relative 
 
b
 
-galactosidase
activity.
 
Assay of Caspase Activity.
 
DO11.10 T cells (2 
 
3
 
 10
 
6
 
 per mil-
liliter) were treated with plate-bound anti-CD3 for 8 h, washed
three times with PBS, and lysed in a buffer containing 10 mM
Tris, pH 7.5, 130 mM NaCl, 1% Triton X-100, 10 mM NaPi,
and 10 mM NaPPi. Cell lysates were centrifuged at 13,000 
 
g
 
, and
the cleared supernatants were collected for protease assays. The
lysates (50 
 
m
 
g) and 10 
 
m
 
g Ac-YVAD–AMC or Ac-DEVD–AFC
were added to 1 ml protease assay buffer containing 20 mM
Hepes, pH 7.5, 10% glycerol, and 10 mM DTT for the caspase-1
assay or 20 mM Pipes, pH 7.2, 100 mM NaCl, 10 mM DTT, 1
mM EDTA, 0.1% (wt/vol) Chaps, and 10% sucrose for the
caspase-3 assay. The mixtures were incubated for 1 or 2 h at 37
 
8
 
C
for the caspase-1 and caspase-3 assays, respectively. Caspase (pro-
tease) activities were determined by monitoring either the release
of AMC at an excitation wavelength of 380 nm and an emission
wavelength of 430–460 nm or the release of AFC at an excitation
of 400 nm and an emission wavelength of 480–520 nm, using a
spectrofluorometer (RF-M2004; Photon Technology Interna-
tional).
 
FasL Expression.
 
DO11.10 T cells or preactivated B6 splenic
T cells were restimulated as indicated (see Figs. 2 and 5), washed
twice with PBS containing 1% BSA and 0.05% sodium azide, and
then incubated with anti-mFasL–PE antibodies (PharMingen) for
45 min at 4
 
8
 
C. After rinsing twice with PBS, the cells were fixed
in PBS/1% paraformaldehyde and analyzed for FasL staining with
a FACScan™. An isotype-matched control antibody was used to
evaluate background staining.
FasL mRNA expression was detected using a semiquantitative
PCR assay. Total RNA was purified from tissues by a guanidin-
ium isothyocyanate/silica gel–based membrane RNeasy method
(QIAGEN Inc.) according to the manufacturer’s instructions.
The resulting RNA (1 
 
m
 
g) was reversed transcribed with Super-
script II (GIBCO BRL) and oligo (dT) primers (GIBCO BRL) as
per the manufacturer’s recommendations. PCR reaction condi-
tions were as follows. Equivalent amounts of cDNA were added
in addition to the following components: 20 mM Tris-Cl, pH
8.0, 50 mM KCl, 0.75 mM MgCl
 
2
 
, 0.2 mM of each dNTP, 0.5
 
m
 
M of each primer (sense primer, 5
 
9
 
-CAGCTCTTCCACCTG- 
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CAGAAGG-3
 
9
 
; antisense primer, 5
 
9
 
-AGATTCCTCAAAAT-
TGATCAGAGAGAG-3
 
9
 
), and 2.5 U of Taq DNA polymerase
(GIBCO BRL). Templates were denatured at 95
 
8
 
C for 3 min,
primer annealing was carried out at 54
 
8
 
C for 1 min, and exten-
sion was performed at 72
 
8
 
C for 1 min. The cycle was repeated 34
times, followed by a final extension at 72
 
8
 
C for 7 min. The num-
ber of amplification cycles chosen for each reaction were deter-
mined to be within the linear range of the assay. To verify that
equivalent amounts of RNA were added to each FasL PCR reac-
tion, amplification of GAPDH housekeeping gene was performed.
Standardization of cDNA was determined by PCR amplification
of GAPDH (sense primer, 5
 
9
 
-CCATGGAGAAGGCTGGGG-3
 
9
 
;
antisense primer, 5
 
9
 
-CAAAGTTGTCATGGATGACC-3
 
9
 
) in
each sample. Amplification conditions were as follows: 95
 
8
 
C for 2
min, 94
 
8
 
C for 40 s, 62
 
8
 
C for 40 s, and 72
 
8
 
C for 1 min, repeated
for 25 cycles. PCR amplification products were separated on
1.5% agarose Tris-borate–EDTA gels and stained with ethidium
bromide, and product band intensities were quantified by Gel
Doc (Bio-Rad Labs.).
 
Results
 
p38 MAPK Is Required for AICD in T Cells.
 
To deter-
mine whether p38 MAPK mediates TCR stimulation–
induced AICD in T cells, we analyzed the effect of the p38
MAPK–specific inhibitor SB203580, a pyridinyl imidazole
compound (52), on AICD in murine DO11.10 T hybrid-
oma cells. Several caspase inhibitors, i.e., YVAD for
caspase-1, DEVD for caspase-3, and zVAD for pan-
caspases, were used as positive controls. T cell AICD as as-
sayed by PI staining was optimally inhibited by YVAD and
DEVD at a concentration of 50 
 
m
 
M (Fig. 1 A, left panel).
A higher dose (100 
 
m
 
M) of YVAD and DEVD proved
toxic to the T cells, as this concentration of inhibitors did
not block AICD. The pan-caspase inhibitor zVAD inhib-
ited AICD more effectively than either YVAD or DEVD,
suggesting that many caspases are involved in AICD. Inter-
estingly, although 10 
 
m
 
M SB203580 did not inhibit AICD,
increasing the concentration of SB203580 to 40 
 
m
 
M did
inhibit AICD efficiently. Consistent with this observation,
DNA fragmentation induced by TCR ligation in DO11.10
T cells was blocked not only by caspase inhibitors but also
by SB203580 (Fig. 1 A, right panel). To test whether this is
also the case in primary T cells, B6 splenic T cells were
preactivated with plate-bound anti-CD3 and anti-CD28
mAbs for 48 h and then restimulated with plate-bound
anti-CD3 for 16 h in the presence of SB203580 or caspase
inhibitors. About 20% of B6 T cells displayed spontaneous
apoptosis in the absence of any stimulation or inhibitors,
and TCR-induced AICD in B6 T cells was significantly
inhibited by both SB203580 and the caspase inhibitors (Fig.
Figure 1. p38 MAPK is required for T cell AICD. (A)
DO11.10 T hybridoma cells were pretreated with differ-
ent concentrations of SB203580 or caspase inhibitors
YVAD, DEVD, and zVAD and then stimulated with
plate-bound anti-CD3 mAb (10 mg/ml) for 16 h. The
number of dead cells was quantitated by PI staining, and
the results are expressed as percent apoptotic cells (left
panel). Data are shown as mean values 6 SEM and are
from one of two independent experiments. DO11.10 T
hybridoma cells were pretreated and then stimulated as in
A. Chromosomal DNA was extracted and analyzed on a
2% agarose gel to detect DNA fragmentation (right
panel). (B) Purified splenic T cells from B6 mice were
activated with plate-bound anti-CD3 and anti-CD28
mAbs for 48 h. Activated T cells were then restimulated
in wells coated with anti-CD3 for 16 h in the presence of
either the caspase inhibitors YVAD, DEVD, or zVAD or
the p38 MAPK inhibitor SB203580. rIL-2 (20 U/ml)
was added to unstimulated and restimulated cells. The
percent apoptotic cells was determined by PI staining
(left panel). Data are shown as mean values 6 SEM and
are from one of three independent and reproducible ex-
periments. DNA fragmentation (right panel) was de-
tected as in A. Data shown are from one of three inde-
pendent and reproducible experiments. 
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1 B). These data imply a role for p38 MAPK in T cell
AICD.
To further investigate how p38 MAPK mediates T cell
AICD as well as the relationship between p38 MAPK,
caspases, and JNK in this process, the kinetics of induction
of AICD and activation of p38 MAPK and JNK induced
by TCR stimulation were analyzed in the presence or ab-
sence of caspase inhibitors. Whereas only z20–30% apop-
tosis was evident at 2 h after stimulation, this level in-
creased to 70–80% apoptosis by 8 h and to 90% apoptosis
by 16 h (Fig. 2 A, top panel). All three caspase inhibitors
suppressed apoptosis, but again zVAD was the most effec-
tive inhibitor. Most interestingly, JNK activation was de-
tectable by 2 h (1.5-fold increase) but was maximal at 8
and 16 h (about a sixfold increase) after stimulation (Fig. 2
A, bottom panel). The kinetics of JNK activation corre-
lated closely with the kinetics of anti-CD3–induced apop-
tosis of DO11.10 T cells. Activation of JNK during T cell
AICD was inhibited by the three caspase inhibitors, indi-
cating that the activities of many caspases are required to
activate JNK. In contrast, the peak of p38 MAPK activa-
tion (seven- to eightfold increase) occurred at 2 h after
stimulation, i.e., z6 h before maximal JNK activation.
The activity of p38 MAPK returned to a basal level by
8–16 h (Fig. 2 A, bottom panel). Note that p38 MAPK
activation was not inhibited by any of the caspase inhibi-
tors used. Interestingly, although the caspase inhibitors did
not reduce p38 MAPK activity in the stimulated B6 T
cells, JNK activity was diminished appreciably (two- to
fourfold) after treatment with each of these inhibitors (Fig.
2 B).
Next, we further analyzed the role of caspases in JNK
Figure 2. p38 MAPK and JNK are activated
during AICD in DO11.10 T hybridoma cells
and primary splenic T cells. (A) DO11.10 T
cells were pretreated with the caspase inhibitors
YVAD, DEVD, or zVAD and were then cul-
tured in anti-CD3 (10 mg/ml)-coated plates for
varying times. The percent of apoptotic cells
was determined by PI staining as in Fig. 1. p38
MAPK was immunoprecipitated with an anti-
p38 MAPK, and p38 MAPK activity in immu-
noprecipitates was measured using GST–ATF-2
as substrate. JNK activity was measured using a
solid-phase JNK assay. Cell lysates were reacted
for 4 h at 48C with GST–c-Jun precoupled to
glutathione–agarose beads, followed by an in
vitro kinase reaction. Data are shown as mean
values 6 SEM and are from one of two inde-
pendent and reproducible experiments. The
relative activities of the p38 MAPK and JNK
were quantitated by densitometric scanning and
are shown below the respective gel lanes. (B)
Splenic T cells from B6 mice were activated
with plate-bound anti-CD3 and anti-CD28
mAbs for 48 h. Activated T cells were then
restimulated in wells coated with anti-CD3 for
16 h in the presence of the caspase inhibitors
YVAD, DEVD, or zVAD. For in vitro kinase
assays of p38 MAPK and JNK, activated T cells
were restimulated with plated-bound anti-CD3
for 2 h and 8 h, respectively, and the relative
activities of p38 MAPK and JNK were assayed
and quantitated as in A. (C) Splenic T cells
from gld mice (left panel) were activated with
plate-bound anti-CD3 and anti-CD28 mAbs
for 48 h. Activated T cells were then restimu-
lated in wells coated with anti-CD3 for 2 and
8 h. JNK and p38 MAPK activities were assayed
as in A. Cell lysates were immunoblotted with
anti–caspase-1 (Casp1) or anti-CPP32 (Casp3),
respectively (left panel). Alternatively, B6
splenic T cells (right panel) were activated as in
B, and activated T cells were then treated with
plate-bound anti-Fas (5 mg/ml) for 8 h in the
presence or absence of zVAD (50 m/M). Activ-
ities of JNK and p38 MAPK and cleavage of
caspase-1 and -3 were assayed as above. A and
B, p29, line 4–5: in the presence of the caspase
inhibitors YVAD, DEVD, and zVAD.1022 p38 MAPK and JNK Control Fas Ligand Expression during T Cell AICD
activation during AICD using two approaches. First, we
reasoned that if JNK activity is dependent on the activa-
tion of caspases initiated by Fas–FasL interaction, JNK ac-
tivity may be very weak or absent in FasL-deficient gld T
cells stimulated with anti-CD3. Splenic T cells from gld
mice were preactivated for 48 h with plate-bound anti-
CD3 and anti-CD28 and restimulated for 2 or 8 h with
plate-bound anti-CD3, and their p38 MAPK and JNK ac-
tivities were determined by in vitro kinase assays. Indeed,
JNK activity was not induced, whereas p38 MAPK was
activated significantly (fivefold) by CD3 ligation in gld T
cells (Fig. 2 C, left panel). Thus, JNK activation induced
by Fas–FasL interaction is impaired in gld T cells, whereas
TCR-mediated p38 MAPK activation remains intact. Sec-
ond, we examined whether the cross-linking of Fas acti-
vates caspase-1, caspase-3, and JNK in preactivated B6
splenic T cells. Activation of procaspase-1 and procaspase-3
was determined by their ability to be cleaved into their
respective mature caspases after anti-Fas stimulation. Cross-
linking Fas with plate-bound anti-Fas antibody resulted
in the activation of caspase-1, caspase-3, and JNK (six- to
sevenfold) in B6 T cells (Fig. 2 C, right panel). Pretreat-
ment of B6 T cells with zVAD completely inhibited JNK
activation. In contrast, neither procaspase-1 nor procas-
pase-3 was cleaved in anti-CD3–restimulated gld T cells
(Fig. 2 C, left panel). Consistent with this observation, no
AICD was seen in anti-CD3–restimulated gld T cells
(data not shown). These data clearly demonstrate that
p38 MAPK is active upstream of caspases and JNK and
that JNK activity lies downstream of caspases in primary
T cells.
p38 MAPK Regulates the Activation of Caspases and JNK.
The data presented above raise the possibility that p38
MAPK is an upstream regulator of caspases and JNK. To
test this possibility, DO11.10 T cells were pretreated
with SB203580 for 1 h and then stimulated with plate-
bound anti-CD3 mAb for 8 h. Caspase-1 and caspase-3 ac-
tivities were assayed using specific fluorescent substrates.
SB203580 pretreatment greatly reduced caspase-1 and
caspase-3 activities, as evidenced by decreased emission
peaks of their fluorescent substrates. (Fig. 3 A). Moreover,
procaspase-1 was cleaved after CD3 ligation, and YVAD,
zVAD, and SB203580 but not DEVD inhibited this cleav-
age (Fig. 3 B, top panel). Similarly, CD3 ligation of
DO11.10 T cells induced the cleavage of procaspase-3, as
revealed by the detection of a 17-kD band (Fig. 3 B, bot-
tom panel). This cleavage of procaspase-3 was undetectable
when the T cells were stimulated in the presence of ei-
ther  the caspase inhibitors or the p38MAPK inhibitor
SB203580. The inhibition of procaspase-3 cleavage by
YVAD but lack of inhibition of procaspase-1 cleavage by
DEVD suggests that caspase-1 or a caspase-1–like mem-
ber(s) lies upstream of caspase-3. Taken together, these data
further indicate that p38 MAPK is an upstream regulator of
caspases.
If p38 MAPK indeed regulates the activity of caspases as
well as JNK, we would expect that the inhibition of p38
MAPK activity by SB203580 should also abrogate JNK
activation during T cell AICD. To address this issue, in
vitro kinase activities of JNK and ERK1 were assayed in
lysates of DO11.10 T cells previously treated with
SB203580 for 1 h and then stimulated with plate-bound
anti-CD3 for 8 h at 378C. SB203580 pretreatment inhib-
ited JNK activity in a dose-dependent manner (Fig. 4 A,
left panel). This inhibition was specific, as SB203580 did
not block ERK1 activation, and SKF106978, an inactive
inhibitor of p38 MAPK, did not interfere with JNK acti-
vation during AICD. Moreover, pretreatment of DO11.10
T cells with either SB203580 or SKF106978 did not affect
JNK activation induced by either CD3 ligation for 15 min
(Fig. 4 A, right panel) or in response to stress stimuli such
as UV and sorbitol (Fig. 4 B). In additional control exper-
iments, SB203580 inhibited p38 MAPK but not ERK1
activity in anti-CD3–stimulated DO11.10 T cells (Fig. 4
A, right panel).
To further exclude the possibility that JNK is inhibited
nonspecifically by SB203580, DO11.10 T cells were stably
transfected with the DN p38 MAPK (p38 [M]) mutant,
and the activities of p38 MAPK and JNK were assayed
during AICD. JNK activity was markedly suppressed by
Figure 3. p38 MAPK regulates caspase activities. (A) DO11.10 T cells
were pretreated for 1 h with 40 mM SB203580 or SKF106978 and then
stimulated for 8 h with plate-bound anti-CD3. The activities of caspase-1
and caspase-3 were assayed using Ac-YVAD–AMC and Ac-DEVD–AFC
as substrates. (B) DO11.10 T cells were pretreated with YVAD, DEVD,
zVAD, and SB203580 for 1 h and then stimulated with plate-bound anti-
CD3 for 8 h. The cells were lysed, and the cleavage of procaspase-1 and
procaspase-3 were detected by immunoblotting with anti–caspase-1
(Casp1) and anti-CPP32 (Casp3) antibodies. Data shown are from one of
three independent and reproducible experiments.1023 Zhang et al.
p38 (M) but not the control pcDNA3 vector (Fig. 4 C).
Note that this suppression of JNK activity was not due to
different amounts of p38 MAPK proteins loaded, as about
a fourfold increase in the amounts of p38 MAPK was seen
in p38 (M)-transfected cells compared with that in
pcDNA3-transfected cells (Fig. 4 C, center panel). On the
other hand, JNK was activated normally in response to
stress stimuli (Fig. 4 D, left panel) or after a short stimula-
tion (15–30 min) with anti-CD3 (Fig. 4 D, right panel).
As the peak of p38 MAPK activation during T cell AICD
occurs at 2 h after CD3 ligation, one would predict that
the addition of SB203580 at $2 h after T cell stimulation
should not affect the amount of T cell apoptosis observed.
To test this possibility, SB203580 was added to DO11.10
T cells that were previously stimulated with anti-CD3 for
4 h. As expected, addition of SB203580 after TCR stimu-
lation did not inhibit AICD, in contrast to what was ob-
served when SB203580 was added to T cells before TCR
stimulation. In control cultures, addition of SKF106978
either before or after TCR stimulation had no effect on
AICD (Fig. 4 E). These data suggest that p38 MAPK may
be responsible for initiating the activation of caspases and
JNK and that p38 MAPK may be an important regulator
of TCR-induced AICD in T cells.
p38 MAPK Regulates FasL Expression. AICD is medi-
ated by Fas–FasL interaction, and JNK has been proposed
to regulate FasL expression in response to stress stimulation
(42, 43). Since we observed that p38 MAPK may regulate
the activation of caspases and JNK, it was of interest to ex-
amine the effect of p38 MAPK on FasL expression during
AICD in T cells. We found that the expression of FasL
was upregulated in a time-dependent manner during
TCR-stimulated AICD in DO11.10 T cells (Fig. 5 A).
Notably, the kinetics of stimulated FasL expression closely
paralleled that of AICD shown in Fig. 2 A. Moreover, a
Fas-Fc chimeric protein that can block Fas–FasL interac-
tion (42) significantly inhibited AICD in DO11.10 T cells
(data not shown). These results confirm that TCR-induced
Figure 4. p38 MAPK is required for JNK
activation during AICD. (A) Left panel,
DO11.10 T cells were pretreated with
SB203580 (0–100 mM) and then stimulated
with plate-bound anti-CD3 for 8 h. JNK ac-
tivity was assayed as in Fig. 2 A, and ERK1
activity was measured using MBP as sub-
strate. Alternatively, JNK activity was assayed
in DO11.10 T cells pretreated with
SKF106978 (0–100 mM) and then stimulated
with plate-bound anti-CD3 for 8 h. The rel-
ative activities of JNK and ERK1 were quan-
titated as in Fig. 2 A. Right panel, the activi-
ties of p38 MAPK, JNK, and ERK1 were
assayed in DO11.10 T cells pretreated with
SB203580 (0–100 mM) and then stimulated
with anti-CD3 for 15 min. (B) DO11.10 T
cells were pretreated with 40 mM of
SB203580 or SKF106798 for 15 min and
then treated with 0.4 mM sorbitol for 30
min. The cells were either left untreated
(UT) or exposed to UV irradiation at 40 J/m2
and were then maintained for a further 30
min at 378C. JNK activity in cell lysates was
assayed and quantitated as in Fig. 2 A. (C)
DO11.10 T cells were stably transfected with
a control plasmid pcDNA3 or with pcDNA3
encoding p38 (M). DO11.10 transfectants
were stimulated with plate-bound anti-CD3
for either 2 or 8 h for the p38 MAPK and
JNK assays, respectively, which were per-
formed and quantitated as in Fig. 2 A. The
amounts of p38 MAPK proteins loaded were
determined by anti-p38 MAPK immuno-
blotting. (D) p38 (M) DO11.10 transfectants
were treated with UV irradiation or sorbitol
as in B (left panel) or were stimulated with
anti-CD3 for 0–120 min (right panel) and lysed.
JNK activity was assayed and quantitated as
in Fig. 2 A. (E) SB203580 or SKF106978,
each at a concentration of 40 mM, was either
added at 1 h before anti-CD3 stimulation or
4 h after anti-CD3 stimulation of DO11.10
T cells. The percent of apoptotic cells was scored by FACS® analysis of PI-stained cells. Data are shown as mean values 6 SEM and are from one of
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T cell AICD is directly dependent on Fas–FasL interac-
tion. Pretreatment of DO11.10 T cells with either caspase
inhibitors or SB203580 reduced FasL expression about
three- to fivefold and 10-fold, respectively (Fig. 5 A, left
panel). Similar results were obtained with primary B6
splenic T cells (Fig. 5 A, right panel). Therefore, inhibi-
tion of p38 MAPK activity may suppress TCR-induced
AICD by the inhibition of FasL expression and conse-
quent disruption of Fas–FasL interaction.
This possibility was addressed by analyzing FasL expres-
sion and AICD induced by CD3 ligation in p38 (M) stably
transfected DO11.10 T cells. In support of a role for p38
MAPK in the control of FasL expression and AICD in T
cells, we found that the capacity of these p38 (M) DO11.10
transfectants to express FasL both at the level of mRNA
level and at the cell surface was significantly impaired (Fig. 5
B, top). To substantiate these observations, we analyzed
FasL expression and the amount of apoptosis in the
pcDNA3 and p38 (M) transfectants in response to different
doses of anti-CD3 (0.001–10 mg/ml). Maximum FasL ex-
pression and apoptosis occurred at 1–10 mg/ml of anti-CD3
stimulation in pcDNA3-transfected cells, and this response
was completely abrogated in p38 (M)-transfected cells (Fig.
5 B, bottom).
It has been shown that IL-2 can upregulate FasL expres-
sion during AICD (53). To investigate whether p38 (M)
blocks FasL expression by downregulating IL-2 production,
rIL-2 was added to p38 (M)-transfected DO11.10 T cells
before CD3 ligation in an attempt to restore FasL expres-
sion. Addition of rIL-2 over a wide concentration range
Figure 5. p38 MAPK regulates FasL
expression. (A) Left panel, DO11.10 T
cells were pretreated with SB203580 or
caspase inhibitors YVAD, DEVD, and
zVAD for 1 h at 378C and then incubated
with plate-bound anti-CD3 for varying
times. At each time point, cells were har-
vested, stained with PE–anti-FasL mAb,
and analyzed by flow cytometry. Data are
shown as mean values 6 SEM and are
from one of three independent and repro-
ducible experiments. Right panel, B6
splenic T cells were preactivated with
plate-bound anti-CD3 and anti-CD28 for
48 h. Activated T cells were pretreated
with either SB203580 or SKF106978 or
caspase inhibitors YVAD, DEVD, and
zVAD and then cultured in wells coated
with anti-CD3. After 16 h, the cells were
assayed for surface FasL expression as in A.
Data are shown as mean values 6 SEM
and are from one of three independent
and reproducible experiments. (B)
DO11.10 T cells stably transfected with
p38 (M) or control plasmid pcDNA3
were either left unstimulated or were
stimulated with plate-bound anti-CD3 for
16 h. Cells were harvested, and RNA was
prepared from all samples, reverse tran-
scribed, amplified using primers specific
for FasL and GAPDH, and electropho-
resed in 1.5% agarose gels. Alternatively,
cells were stained with PE–anti-FasL mAb
or PI and analyzed by flow cytometry
(center and right panels, respectively).
The FasL expression data (fluorescence in-
tensity) are shown as overlays (solid line,
negative control; dashed line, unstimu-
lated cells; and dotted line, stimulated
cells) and are from one of three indepen-
dent experiments. Alternatively, DO11.10
T cells stably transfected with p38 (M) or
control plasmid pcDNA3 were either left
unstimulated or stimulated with different
concentrations of plate-bound anti-CD3
(0.001–10 mg/ml), and FasL expression
and apoptosis were analyzed by flow cy-
tometry. The data shown are from one of
three independent and reproducible experiments. (C) p38 (M)- or pcDNA3-transfected DO11.10 T cells were cultured in wells coated with anti-CD3 in
the presence of different concentrations of rIL-2 (10–80 U/ml) for 16 h. Percent FasL expression and apoptotic cells was quantitated as in B. Data shown
are from one of three independent and reproducible experiments.1025 Zhang et al.
had only a marginal effect on the stimulation of FasL ex-
pression and AICD in either the p38 (M) or pcDNA3 con-
trol vector transfectants (Fig. 5 C). The failure of rIL-2 to
further increase FasL expression and AICD in the latter
control transfectants is likely due to the high amount of IL-2
secreted by these cells (our unpublished observations).
Thus, the p38 (M)-mediated suppression of FasL expression
and AICD can not be ascribed simply to a lack of available
IL-2, but rather may result from a direct effect of p38
MAPK on the regulation of FasL gene transcription. Evi-
dence in support of this idea was obtained by demonstrating
that FasL promoter transcriptional activity was significantly
reduced after transfection of a FasL promoter–luciferase re-
porter gene construct into p38 (M) DO11.10 T cell stable
transfectants (Fig. 6). In contrast, FasL promoter activity
was enhanced upon TCR stimulation in DO11.10 cells
transfected with the control pcDNA3 vector.
JNK Activity Is Required for FasL Expression. Earlier in
this report, we showed that inhibition of caspase activation
by YVAD, DEVD, or zVAD not only blocks T cell AICD
(Fig. 1) but also downregulates FasL expression in T cells
(Fig. 5 A). Since JNK functions downstream of caspases, we
next determined whether a block in JNK activity also sup-
presses FasL expression and AICD. FasL expression and
AICD were assayed in DO11.10 T cells stably transfected
with DN–JNK-2 or WT–JNK-2. The activity of JNK but
not p38 MAPK was selectively inhibited in the DN–JNK-2
DO11.10 transfectants (Fig. 7 A). Both TCR-induced FasL
expression and AICD were inhibited virtually completely
in DN–JNK-2 but not control WT–JNK-2 DO11.10
transfectants (Fig. 7 B). Thus, JNK also regulates FasL ex-
pression during AICD in T cells.
Discussion
We analyzed the mechanism of regulation of FasL ex-
pression and its role in the FasL–Fas-dependent signaling
cascade by which TCR stimulation potentiates AICD in T
cells. Our results demonstrate that p38 MAPK plays a piv-
otal role in T cell AICD by initiating FasL expression,
which then leads to the FasL–Fas-dependent activation of
caspases and JNK. JNK functions downstream of caspases
and together with p38 MAPK upregulates FasL expression
and elicits caspase-mediated AICD in T cells.
JNK activity has been shown to mediate AICD in pri-
mary T cells (44, 45), but the mechanism involved is un-
known. In addition, stress-induced FasL expression in T
cells is mediated by a MEKK1-regulated response element
in the FasL promoter (42), and AP-1 transcriptional activa-
Figure 6. p38 MAPK regulates FasL promoter activity. p38 (M) or
pcDNA3 DO11.10 stable transfectants were transiently transfected with a
FasL-511 luciferase construct, maintained in medium for 36 h at 378C, and
were then either left unstimulated or were stimulated with plate-bound
anti-CD3 for 16 h. Luciferase activity in whole cell lysates was assayed and
is shown as mean value 6 SEM. Transfection efficiency was monitored by
cotransfection of a pUC19 plasmid encoding b-galactosidase. Similar re-
sults were obtained in three independent and reproducible experiments.
Figure 7. JNK regulates FasL expression and AICD. (A)
DO11.10 T cells transfected with WT–JNK-2 or DN–
JNK-2 were cultured for 8 h in the absence or presence of
plate-bound anti-CD3. Cell lysates were reacted with 10
mg of either GST–c-Jun (left panel) precoupled to glu-
tathione–agarose beads for 4 h at 48C or immunoprecipi-
tated with anti-p38 MAPK (right panel) and were then as-
sayed for JNK or p38 MAPK activity, respectively. (B)
DO11.10 T cells stably transfected with WT–JNK-2 or
DN–JNK-2 were either left unstimulated or were stimu-
lated with different concentrations of plate-bound anti-
CD3 (0.001–10 mg/ml) for 16 h. The cells were harvested,
stained with PE–anti-FasL or PI, and analyzed for percent
surface Fas expression and apoptotic cells by flow cytome-
try (solid line, negative control; dashed line, unstimulated
cells; and dotted line, stimulated cells). Data are shown as
mean values 6 SEM and are from one of three indepen-
dent and reproducible experiments.1026 p38 MAPK and JNK Control Fas Ligand Expression during T Cell AICD
tion site binding proteins, including c-Jun and ATF-2,
regulate transcription of this promoter (43). We investi-
gated the regulation of FasL expression by p38 MAPK in T
cells and found that both the transcription and surface ex-
pression of FasL in DO11.10 T cells are significantly inhib-
ited by the DN p38 MAPK (p38 [M]) mutant. Since IL-2
can enhance FasL expression during AICD (53), we con-
sidered the possibility that inhibition of FasL expression by
p38 (M) results from a low level of IL-2 in DO11.10 T
cells. However, the addition of rIL-2 at varying concentra-
tions to p38 (M) DO11.10 transfectants failed to restore
FasL expression, suggesting that blockade of FasL expres-
sion by p38 (M) was not due to a lack of sufficient IL-2.
Rather, our FasL reporter gene assays demonstrated that
p38 MAPK directly regulates FasL promoter activity. Re-
cently, the cyclosporin A–sensitive and Ca21-dependent
transcription factors NFAT (nuclear factor and activator
of transcription) and Egr3 were reported to regulate FasL
transcription by binding positive regulatory elements up-
stream of the FasL coding sequence (51, 54, 55). Since we
(27) and others (56) have shown that optimal p38 MAPK
activation in T cells requires costimulation by Ca21, p38
MAPK may phosphorylate ATF-2 and Ca21-dependent
transcription factors or otherwise induce the expression of
c-Jun (27). ATF-2 and c-Jun bind to the FasL promoter
and activate FasL gene transcription. Thus, p38 MAPK
elicits caspase activation via the regulation of FasL expres-
sion. This notion is supported by our observation that the
activities of both caspase-1 and caspase-3 during AICD
were significantly inhibited by SB203580.
Both caspases and stress-related MAPKs are involved in
apoptosis in various cell types, but the relationship be-
tween them has not been fully elucidated. JNK- as well as
p38 MAPK–dependent pathways may be activated during
Fas-induced cell death in Jurkat T cells (40, 46, 47).
Whereas activation of p38 MAPK is dependent upon
caspase-1–like members, p38 MAPK activity is not re-
quired for Fas-mediated apoptosis (46, 47). However, the
upstream activator of p38 MAPK, MKK3 or MKK6b, is
involved in Fas-induced cell death (46, 47), indicating that
p38 MAPK may mediate some cellular responses that pre-
cede Fas-mediated apoptosis (40, 47). It is noteworthy that
Jurkat T cells and primary T cells differ in terms of their
requirements for activation of MAPKs (27). Moreover,
JNK has been implicated in an important role in the regu-
lation of AICD in primary T cells (44, 45), but it is not re-
quired for anti-Fas–induced Jurkat T cell death (35). These
findings indicate that the signaling mechanism(s) of TCR-
induced AICD in primary T cells may be different from
that of anti-Fas–induced cell death in Jurkat T cells. Both
primary naive T cells and DO11.10 T cells express low
levels of Fas and FasL, and the expression of Fas and FasL is
upregulated upon TCR ligation in primary T cells and
DO11.10 T cells. Therefore, the mechanism of TCR-
induced AICD in DO11.10 T cells may be similar to that
in primary T cells.
We examined the relationship between the activation of
p38 MAPK, caspase, and JNK during AICD. Analyses of
T cells from FasL-deficient gld mice, anti-Fas–induced Fas
cross-linking in B6 splenic T cells, and DO11.10 T cells
demonstrated that p38 MAPK is active upstream of caspases
and JNK and that JNK activity lies downstream of caspases.
Furthermore, JNK activity was shown to require caspase ac-
tivity, as pretreatment of T cells with YVAD, DEVD, and
zVAD before TCR stimulation blocked the activation of
JNK but not p38 MAPK. Interestingly, a block in caspase
activation resulted in the downregulation of FasL expres-
sion. Caspases are upstream regulators of JNK (35, 40, 41),
Figure 8. Model of regulation of FasL expression during
TCR-induced T cell AICD. In this model, TCR ligation
leads to the activation of PTKs, which results in the activa-
tion of p38 MAPK. p38 MAPK then phosphorylates sev-
eral nuclear transcription factors (e.g., ATF-2), which may
bind to the FasL promoter and activate FasL gene tran-
scription. Transcribed FasL protein translocates from the
cytoplasm to the plasma membrane, interacts with Fas
which then recruits FADD to bind to its death domain.
This FasL–Fas interaction initiates a caspase cascade that
subsequently activates JNK. Activated JNK promotes
AICD by regulating FasL expression. Thus, p38 MAPK
and JNK may preferentially regulate FasL expression at
early and later times after activation, respectively, perhaps
by the phosphorylation and activation of distinct transcrip-
tion factors for the FasL promoter. Consistent with this
model, we observed that inhibition (^) of p38 MAPK,
JNK, and caspase activity blocks T cell AICD.1027 Zhang et al.
and JNK may participate in stress-induced cell death by
the regulation of FasL expression (42, 43). Moreover, p21-
activated kinase (PAK) is required for Fas-induced JNK
activation in Jurkat T cells (41). Since JNK acts down-
stream of PAK, the latter finding suggests that JNK func-
tions downstream of caspase activity. Thus, it is possible
that caspases regulate FasL expression via JNK during
AICD. Indeed, we found that DN–JNK significantly in-
hibits both FasL expression and AICD. Consistent with
this model, T cells from JNK-1– and JNK-2–deficient
mice exhibit decreased AICD, suggesting a role for JNK
in the regulation of T cell apoptosis in primary T cells
(44, 45).
Our observations are consistent with a novel model in
which p38 MAPK and JNK both regulate FasL expression
during TCR-induced T cell AICD (Fig. 8). In this model,
p38 MAPK acts early during the first 2 h after TCR stimu-
lation in the apoptotic cascade to activate FasL expression.
Subsequently, 2–8 h after TCR stimulation, FasL–Fas in-
teraction and the Fas-mediated activation of caspases stim-
ulate JNK to further upregulate FasL expression, possibly
via the phosphorylation of c-Jun and/or ATF-2, which
each bind to the FasL promoter. Thus, p38 MAPK and
downstream JNK appear to converge to regulate FasL ex-
pression at different times after TCR stimulation to elicit
maximal AICD observed at $16 h.
The model proposed supports our previous finding that
p38 MAPK activity is essential for the TCR-stimulated in-
duction of c-Jun expression during the activation of pri-
mary T cells, perhaps due to its ability to phosphorylate
various transcription factors (e.g., ATF-2) that control
c-Jun gene activation (27). This may explain why both
c-Jun and ATF-2 are involved in the regulation of FasL pro-
moter activity. An increase in FasL promoter activity po-
tentiated by p38 MAPK via ATF-2, c-Jun, or other tran-
scription factors would enable FasL to be synthesized
initially at a low level and then translocate to the plasma
membrane, where it can bind to Fas. Membrane-associated
FasL–Fas interactions will recruit FADD, activate caspases,
and lead to enhanced JNK activity and the phosphoryla-
tion of c-Jun and ATF-2. This may allow c-Jun and ATF-2
to function synergistically in a positive feedback loop to
further upregulate FasL promoter activity and enable the
synthesis of sufficient FasL to trigger the caspase cascade
that results in T cell apoptosis. Consistent with this model,
it is interesting that p38 MAPK was recently shown to reg-
ulate FasL expression during AICD of murine T cell hybrid-
omas (57). Analyses of the role of ATF-2 and c-Jun, as
well other transcription factors, in transcriptional com-
plexes that bind to the FasL promoter region are required
to formally prove this model.
In summary, we demonstrate that the biological rele-
vance of our studies is the novel observation that the inte-
gration of p38 MAPK– and caspase-dependent JNK activi-
ties results in optimal FasL expression and consequent T
cell AICD. p38 MAPK and JNK may each preferentially
phosphorylate and activate different transcription factors,
e.g., ATF-2 and c-Jun, respectively, which may interact in
a transcription complex to regulate FasL expression. These
findings are particularly interesting in view of our previous
report that p38 MAPK mediates signal integration of
TCR/CD28 costimulation in primary murine T cells, and
that this integration includes the activation of JNK for op-
timum T cell responsiveness (27). Thus, it will prove im-
portant to further elucidate how p38 MAPK and JNK ac-
tivities govern whether T cells follow a pathway of (a)
deletion via AICD leading to immune tolerance or (b) ac-
tivation leading to immune responsiveness.
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